OncoBEAM testing for melanoma

Publications melanoma

Rowe SP, Luber B, Makell M, et al. (2018) From Validity to Clinical Utility: The Influence of Circulating Tumor DNA on Melanoma Patient Management in a Real-World Setting. Mol Oncol. 12(10):1661–1672. Links: Pubmed Free PDF

Santiago-Walker A, Gagnon R, Mazumdar J, et al. (2016) Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAF and MEK Clinical Trials. Clin Cancer Res. 22(3):567-74. Links: Pubmed Free PDF

Lipson EJ, Velculescu VE, Pritchard TS, et al. (2014) Circulating Tumor DNA Analysis as a Real-Time Method for Monitoring Tumor Burden in Melanoma Patients Undergoing Treatment with Immune Checkpoint Blockade. J Immunother Cancer. 2(1):42. Links: Pubmed Free PDF

Ascierto PA, Minor D, Ribas A, et al. (2013) Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma. J Clin Oncol. 31 (26): 3205–3211. Link: Pubmed